Navigation Links
Therapeutic nanoparticles give new meaning to sugar-coating medicine
Date:9/22/2009

A research team at the National Institute of Standards and Technology (NIST) studying sugar-coated nanoparticles for use as a possible cancer therapy has uncovered a delicate balancing act that makes the particles more effective than conventional thinking says they should be. Just like individuals in a crowd respecting other people's personal space, the particles work because they get close together, but not too close.

In cooperation with colleagues at The Johns Hopkins University, Dartmouth College, the University of Manitoba and two biopharmaceutical companies, the NIST team has demonstrated* that the particlesessentially sugar-coated bits of iron oxide, about 100 nanometers wideare potent cancer killers because they interact with one another in ways that smaller nanoparticles do not. The interactions, thought by many bioengineers to be undesirable, actually help the larger particles heat up better when subjected to an alternating magnetic field. Because this heat destroys cancer cells, the team's findings may help engineers design better particles and treatment methods.

Nanoparticles hold the promise of battling cancer without the damaging side effects of chemotherapy or radiation treatment. Minuscule balls of iron oxide can be coated with sugar molecules making them particularly attractive to resource-hungry cancer cells. Once the particles are injected, cancer cells would then ingest them, and doctors would then be able to apply an alternating magnetic field that causes the iron oxide centers to heat, killing the cancer but leaving surrounding tissue unharmed.

Two biotech companies, Micromod Partikeltechnologie and Aduro BioTech, created particles that showed great potential in treating cancers in mice, and they asked NIST to help understand why it worked so well. "But they sent us particles that were much larger than what the conventional wisdom says they should be," says NIST materials scientist Cindi Dennis. "Larger particles are more strongly magnetic and tend to clump together, which makes them large enough to attract the body's defense systems before they can reach a tumor. The companies' nanoparticles, however, did not have this problem."

Neutron scattering probes at the NIST Center for Neutron Research revealed that the particles' larger iron oxide cores attract one another, but that the sugar coating has fibers extending out, making it resemble a dandelionand these fibers push against one another when two particles get too close together, making them spring apart and maintain an antibody-defying distance rather than clumping. Moreover, when the particles do get close, the iron oxide centers all rotate together under the influence of a magnetic field, both generating more heat and depositing this heat locally. All these factors helped the nanoparticles destroy breast tumors in three out of four mice after one treatment with no regrowth.

"The push-pull is part of a tug of war that fixes the distance between nanoparticles," Dennis says. "This suggests we can stabilize interacting particles in ways that potentially pay off in the clinic."


'/>"/>

Contact: Chad Boutin
boutin@nist.gov
301-975-4261
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Related biology news :

1. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
2. Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes
3. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
4. New DNA and RNA aptamers offer unique therapeutic advantages
5. Got zinc? New zinc research suggests novel therapeutic targets
6. Stem cell research: From molecular physiology to therapeutic applications
7. Triggering muscle development -- a therapeutic cure for muscle wastage?
8. New nanoparticles could revolutionize therapeutic drug discovery
9. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
10. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
11. NIH announces new program to develop therapeutics for rare and neglected diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/6/2017)... ... 06, 2017 , ... On Tuesday, October 24th, ABC² (Accelerate ... first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. ... open to the public, but registration is required. , WHAT: ABC² Brain ...
Breaking Biology Technology: